RSC Medicinal 浪花直播
The journal for research and review articles in medicinal chemistry and related drug discovery science.
Editor-in-Chief: Mike Waring
Open Access: Hybrid

RSC Medicinal 浪花直播 publishes significant research in medicinal chemistry and related drug discovery science.
ISSN: 2632-8682
Indexed in: Web of Science, Scopus, PubMed Central
Journal Impact factor
3.6 (2024)
First decision time (all)
14 days
First decision time (peer reviewed)
32 days
Scope
Research articles published in this journal must show a breakthrough or significant advance on previously published work, or bring new thinking or results that will have a strong impact in their field.
Examples of areas within the journal's scope are:
- Design, synthesis and biological evaluation of novel chemical entities or biotherapeutic modalities. To be suitable for publication these must exhibit significant potential as new pharmacological agents, tools, probes or potential drugs.
- Modifications of known chemical entities or biotherapeutic modalities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or provide other information of significant value, for example, the identification of a new target or mode of action for a known agent. Routine modifications with minimal or no improvement are not suitable for RSC Medicinal 浪花直播.
- Novel methodologies and technologies in the broader chemical and biological sciences (for example, enabling synthetic chemistry, chemical biology, -omics sciences, nanoscience) with application to drug discovery, target identification or elucidation of the mechanism of action. Biological studies should present sufficient innovation with respect to the chemistry.
- Computational studies are welcome where they significantly advance medicinal chemistry knowledge. Studies that use established computational methods should include an original prediction and be accompanied by new experimental data which validates the prediction made. Studies that report novel computational methodology must demonstrate its use in medicinal chemistry through comparison with experimental data. Computational research that does not clearly relate the results obtained to experimental data or that has no demonstrated utility (or where the utility is unlikely to advance the field significantly) is not suitable for RSC Medicinal 浪花直播. Docking studies presented without experimental data are not suitable for publication in the journal.
- Studies that examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics.
- Studies that present new insights into drug design based on analysis of existing experimental datasets or new theoretical approaches if supported by experimental evidence.
- Studies presenting new drug delivery systems with novel chemical agents are welcomed, in particular those that involve chemical modification of the delivery system of conjugation with novel delivery vectors. Those that focus solely on formulations of known drugs are not suitable for publication in RSC Medicinal 浪花直播.
Note that studies where new or existing compounds are tested as pharmacological agents will only be considered if they are carried out in the presence of clear positive and negative controls. Studies of this type should include a clearly defined and hypothesis-driven compound design rationale. Potential antimicrobial agents should be tested for cytotoxicity and activity against non-related pathogens.
To help editors and referees assess the significance of each submitted manuscript we ask all authors on submission to provide a brief statement of significance. This should contain one sentence to summarise the most important finding(s) in the manuscript and a second sentence to say why this is a significant advance in the field. This significance statement should focus specifically on the importance of the piece of research being submitted, rather than the importance of the field.
Readership
Researchers in academia and industry studying medicinal chemistry, pharmacology, and topics in the wider chemical, biological and materials sciences with application to biological problems.
Information for authors
Want to publish in this journal? Our author guidelines explain how to prepare and submit your article and provide useful information on the review and publication process including transfers, revisions and any article processing charges (APCs) that may apply.
You can read our payments and funding information for further details about APCs, which may apply for publishing open access in this journal, as well available discounts and waivers.
You may be able to publish open access in this journal, with no APC to pay, if your institution has an open access agreement with us. You can use our journal finder tool to between us and your institution.
Meet the team




Sankar K. Guchhait
Associate editor
National Institute of Pharmaceutical Education and Research (NIPER
View profile






Timor Baasov
Israel Institute of Technology
Andreas Bender
University of Cambridge
Julian Blagg
Institute of Cancer Research
Margaret Brimble
University of Auckland
Mark Bunnage
Vertex
Christopher Burns
Amplia Therapeutics Limited
Andrea Cavalli
University of Bologna
Young-Tae Chang
POSTECH
James Crawford
Altos Labs
Matthew Duncton
Rigel Pharmaceuticals Inc
Stephen Frye
University of North Carolina at Chapel Hill
Matthew Fuchter
University of Oxford
Sylvie Garneau-Tsodikova
University of Kentucky
Jayanta Haldar
Jawaharlal Nehru Centre for Advanced Scientific Research
Gyoonhee Han
Yonsei University
Mike Hann
GSK Medicines Research Centre
Christian Heinis
EPFL
Laura H. Heitman
Leiden University
Yoshinori Ikeura
Axcelead Drug Discovery Partners
Ahmed Kamal
NIPER
Robert Langer
Massachusetts Institute of Technology (MIT)
Steven V Ley
University of Cambridge
María Luz López Rodríguez
Complutense University of Madrid
Christa Muller
University of Bonn
Roberto Pellicciari
University of Perugia
David Rees
Astex Therapeutics
Motonari Uesugi
Kyoto University
John C Vederas
University of Alberta
Paul Wender
Stanford University
Zhen Yang
Peking University
Ming-Qiang Zhang
Amgen
Katie Lim
Executive Editor
Hannah Fowler
Deputy Editor
Emily Cuffin-Munday
Development Editor
Sarah Anthony
Editorial Production Manager
Nicola Burton
Publishing Editor
Tom Cozens
Publishing Editor
Ryan Kean
Publishing Editor
Thomas Hitchings
Publishing Editor
Donna Smith
Publishing Editor
Sam Keltie
Publisher

Emily Prior
Editorial Assistant
Read this journal
More from this journal
Contact the journal team
We're here to help. Contact the journal team if you have any questions about publishing your paper with us.
Sign up for journal email alerts
Get table of contents alerts and notifications about calls for papers, themed issues and more.